Aripiprazole in Children and Adolescents With Bipolar Disorder and Attention Deficit Hyperactivity Disorder (ADHD)
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
There is a scarcity of clinical trials assessing the effects of medications in children with
bipolar disorder. This study aims to assess the efficacy of Aripiprazole (a novel
anti-psychotic drug) for the treatment of children and adolescents with bipolar disorder
comorbid with ADHD. The study design is a 8-week randomized, double blind, parallel group
trial. Patients were randomized to either aripiprazole or placebo.
The main hypotheses are:
1. Aripiprazole will significantly reduce maniac scores compared to placebo
2. Aripiprazole will significantly reduce ADHD scores compared to placebo